It’s been recently announced on the news that JP Morgan, Berkshire Hathaway and e-commerce giant Amazon have announced they have a new system for getting healthcare that could cut out the “middleman” when it comes to consumer purchases. It’s a complex issue to explain since the layers of healthcare all have profits flowing from pharmaceutical companies, to drug retailers like CVS and Walgreens, healthcare providers and networks as well the insurance companies. But in wake of this announcement meany healthcare stocks took a big hit in the stock market, though Paul Mampilly, an expert at Banyan Hill Publishing warned this was coming. What Mampilly says is that Amazon’s entering the drug sale marketplace will cause healthcare stocks to drop way down, and when they reach a point that makes them look good to buy, investors may be eager to snatch them up. But the bad news is they’re not likely to ever rebound.
Paul Mampilly doesn’t simply tell his followers what they want to hear. He gives them real advice on how to find good stocks that he himself learned during his Wall Street career, and he’s not a broker at Banyan Hill; he’s an author who tells his audience how to build their own portfolio. Prior to joining Banyan Hill, he spent several years in the hedge fund industry and more than 10 years in big banking. He got his bachelor’s degree in economics and finance from Montclair State University, and his master’s from Fordham University. He began in banking as a researcher for Deutsche Bank in 1991 and moved up the ranks in the offices of ING, Sears, Banker’s Trust and others.
Paul Mampilly gained major recognition from Barron’s magazine in 2006 when he joined the team at Kinetics International Fund and helped raise client AUM from $6 billion to $25 billion. He was touted for pooling client investments in funds that brought upwards of 40% in annual returns. Paul Mampilly also invested $50 million in alternative funds during the 2008 Templeton Foundation competition and ended with $88 million despite the recession reaching its peak at that time. He also was an early investor in Netflix and Sarepta Therapeutics prior to their stock reaching incredible highs. Mampilly’s success enabled him to retire from the corporate life early, but he feels his work is just begun in informing his audience on how to make stock investing work for them.
Paul Mampilly’s Social Media: twitter.com/Paul_M_Guru